AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Schrödinger vs Insilico Medicine

Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.

VS
Schrödinger official logo and brand icon

Schrödinger

Enterprise
Visit WebsiteFull Review
Insilico Medicine official logo and brand icon

Insilico Medicine

Enterprise
Visit WebsiteFull Review

Verdict by Category

AI content generation failed. Refresh the page to try again.
View Schrödinger View Insilico Medicine
Feature & Spec Matrix

Detailed Comparison25 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Schrödinger
Schrödinger
Insilico Medicine
Insilico Medicine
Pricing Model
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
EnterpriseCustom Enterprise Biotech / Pharma Licensing for PandaOmics, Chemistry42, and inClinico — Partnership inquiry
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
Academic licensing available at reduced rates; commercial pricing via sales team
No free access — platform licensing and drug discovery collaborations via enterprise agreements
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Pharmaceutical companies and biotechs seeking to accelerate drug discovery from target identification to clinical prediction using generative AI and automated chemistry
Enterprise & Scalability
Difference
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
Pharma.AI platform available for licensing and collaboration agreements with major pharma companies; HKEX listed (3696); regulatory filings in multiple jurisdictions; automated robotic lab integration; multi-country R&D centers
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Physics-based molecular simulation: Maestro, Glide, Jaguar, Prime, and FEP+ for drug and materials discovery
Difference
Schrödinger Advantage
Not listed
Bunsen AI co-scientist (July 2026) for hypothesis generation, experiment design, and molecular insight
Difference
Schrödinger Advantage
Not listed
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Schrödinger Advantage
Not listed
Structure-based drug design, ADMET prediction, and quantum chemistry in one platform
Supported
Supported
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Schrödinger Advantage
Not listed
Drug discovery pipeline with BMS, Sanofi, and Takeda — FY26 guidance raised to $65-75M
Supported
Supported
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Schrödinger Advantage
Not listed
$255.87M revenue in 2025 with 23% growth — NASDAQ listed (SDGR)
Difference
Schrödinger Advantage
Not listed
500+ enterprise customers including top 20 global pharma companies
Difference
Schrödinger Advantage
Not listed
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Schrödinger Advantage
Not listed
Rentosertib (ISM001-055) — world's most advanced fully AI-discovered drug in Phase 3 for IPF
Difference
Not listed
Insilico Medicine Advantage
31+ drug programs across 29 targets in cancer, fibrosis, CNS, immunity, and aging
Difference
Not listed
Insilico Medicine Advantage
Generative AI for de novo molecule design against novel and known drug targets
Difference
Not listed
Insilico Medicine Advantage
Automated robotic laboratory in Suzhou connected directly to the AI platform
Difference
Not listed
Insilico Medicine Advantage
300+ patents filed, 200+ peer-reviewed publications in top scientific journals
Difference
Not listed
Insilico Medicine Advantage
Chemistry42 generative AI designs novel molecules not found in existing chemical libraries
Difference
Not listed
Insilico Medicine Advantage
PandaOmics AI for target identification using multi-omics, literature, and clinical data
Difference
Not listed
Insilico Medicine Advantage
Listed on Hong Kong Stock Exchange (HKEX: 3696) — founded 2014 at Johns Hopkins University
Difference
Not listed
Insilico Medicine Advantage
Schrödinger icon

Schrödinger Pros & Cons

Pros

  • 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
  • Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
  • FEP+ delivers industry-leading accuracy in binding affinity prediction
  • NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
  • 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
  • Materials science applications extend reach to battery, semiconductor, and chemical sectors
  • Cloud-hosted subscriptions eliminate on-premise infrastructure burden

Cons

  • Software is expensive — enterprise pricing puts it out of reach for smaller labs
  • Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
  • Drug discovery segment revenue is milestone-dependent and lumpy
  • Platform learning curve is steep without computational chemistry background
  • Competition from newer, purely AI-native platforms is intensifying
Insilico Medicine icon

Insilico Medicine Pros & Cons

Pros

  • World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
  • End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
  • 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
  • Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
  • Automated robotic lab in Suzhou closing the loop between AI design and physical testing
  • Global presence: US, China, Canada, Middle East — with partnerships across big pharma
  • Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing

Cons

  • Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
  • Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
  • Dual-track model (platform + internal pipeline) adds operational complexity
  • Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
  • Listed on HKEX (Hong Kong) — less accessible to US institutional investors
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Insilico Medicine vs DAX Copilot Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Insilico Medicine and DAX Copilot in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare